Impact of Neoadjuvant Chemotherapy Cycles on Survival of Patients with Advanced Ovarian Cancer: a French national multicenter study (FRANCOGYN)
ConclusionIn a large series of advanced ovarian cancer, patients receiving late IDS (≥ 5 NAC cycles) seem to show a poorer prognosis than patients operated on earlier. The survival appears to be mainly determined by optimal resection and response to chemotherapy.
Source: European Journal of Obstetrics and Gynecology and Reproductive Biology - Category: OBGYN Source Type: research
More News: Biology | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | France Health | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | OBGYN | Ovarian Cancer | Ovaries | Statistics | Study